Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents | Zendy

Mohammad Z. Ahmed | Zendy; Qamar Zia | Zendy; Anzarul Haque | Zendy; Ali S. Alqahtani | Zendy; Omer M. Almarfadi | Zendy; Saeed Banawas | Zendy; Mohammed S. Alqahtani | Zendy; Keshav Lalit Ameta | Zendy; Shafiul Haque | Zendy

Open Access

Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents

Author(s) -

Mohammad Z. Ahmed,

Qamar Zia,

Anzarul Haque,

Ali S. Alqahtani,

Omer M. Almarfadi,

Saeed Banawas,

Mohammed S. Alqahtani,

Keshav Lalit Ameta,

Shafiul Haque

Publication year - 2021

Publication title -

journal of infection and public health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.983

H-Index - 35

eISSN - 1876-035X

pISSN - 1876-0341

DOI - 10.1016/j.jiph.2021.01.016

Subject(s) - chemistry , pharmacology , docking (animal) , drug repositioning , in silico , virtual screening , drug , drug discovery , biochemistry , medicine , nursing , gene

The emergence and spread of SARS-CoV-2 throughout the world has created an enormous socioeconomic impact. Although there are several promising drug candidates in clinical trials, none is available clinically. Thus, the drug repurposing approach may help to overcome the current pandemic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research